Overview

Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This study will investigate the effectiveness of desloratadine in treating subjects with allergic rhinitis (AR) who meet the criteria for intermittent allergic rhinitis.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Desloratadine
Loratadine